Literature DB >> 1709519

The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis.

H B Berntzen1, U Olmez, M K Fagerhol, E Munthe.   

Abstract

L1 is a major granulocyte and monocyte protein, released during activation and turnover of such cells. Blood and synovial fluid (SF) from 41 patients with rheumatoid arthritis (RA) and 6 patients with osteoarthritis (OA), were analyzed for L1 and the acute phase proteins C-reactive protein, orosomucoid, haptoglobin, alpha 1-antitrypsin and albumin as well as for differential leukocyte count. L1 levels in plasma and SF showed highly significant differences (p less than 0.0001), between the RA and OA patients. All the OA patients had normal plasma concentrations of L1 and low concentrations of L1 in SF. All the RA patients had elevated plasma levels of L1 and high L1 concentrations in SF. In the RA patients, the ratios between the protein concentrations in SF and blood were 3.29 for L1 and less than or equal to 0.64 for the acute phase proteins. In the SF, the L1 levels did not correlate with the monocyte count, while a low, positive correlation was found between L1 and the granulocyte count. The high L1 concentrations observed in SF from RA patients probably reflected an increased turnover of leukocytes in the inflamed joints. In SF from RA patients, high L1 concentrations were found in joints with a high amount of swelling. The present study suggests that L1 may represent a marker of both local and systemic inflammation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1709519     DOI: 10.3109/03009749109165280

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  25 in total

1.  Production and release of antimicrobial and immune defense proteins by mammary epithelial cells following Streptococcus uberis infection of sheep.

Authors:  Maria Filippa Addis; Salvatore Pisanu; Gavino Marogna; Tiziana Cubeddu; Daniela Pagnozzi; Carla Cacciotto; Franca Campesi; Giuseppe Schianchi; Stefano Rocca; Sergio Uzzau
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

2.  Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein.

Authors:  Jana Hurnakova; Hana Hulejova; Jakub Zavada; Martin Komarc; Lucie Andres Cerezo; Herman Mann; Jiri Vencovsky; Karel Pavelka; Ladislav Senolt
Journal:  Clin Rheumatol       Date:  2018-04-14       Impact factor: 2.980

3.  Clinical significance of serum calprotectin level for the disease activity in active rheumatoid arthritis with normal C-reactive protein.

Authors:  Yanping Wang; Ying Liang
Journal:  Int J Clin Exp Pathol       Date:  2019-03-01

4.  Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis.

Authors:  Hilde Berner Hammer; Sigrid Odegard; Magne K Fagerhol; Robert Landewé; Désirée van der Heijde; Till Uhlig; Petter Mowinckel; Tore K Kvien
Journal:  Ann Rheum Dis       Date:  2007-01-18       Impact factor: 19.103

5.  Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort.

Authors:  Miriam García-Arias; Dora Pascual-Salcedo; Susana Ramiro; Marie-Eve Ueberschlag; Thomas M Jermann; Carlos Cara; Emilio Martín-Mola; Alejandro Balsa
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

6.  High expression of myeloid-related proteins 8 and 14 characterizes an inflammatorily active but ineffective response of macrophages during leprosy.

Authors:  Cord H Sunderkötter; Jane Tomimori-Yamashita; Verena Nix; Solange M Maeda; Anca Sindrilaru; Mario Mariano; Clemens Sorg; Johannes Roth
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

7.  Calprotectin levels in patients with rheumatoid arthritis to assess and association with exercise treatment.

Authors:  Ayse Acar; Savas Guzel; Banu Sarifakioglu; Eda Celik Guzel; Aliye Yildirim Guzelant; Ceyda Karadag; Lebriz Kiziler
Journal:  Clin Rheumatol       Date:  2016-04-19       Impact factor: 2.980

Review 8.  Calprotectin: Clinical Applications in Pediatrics.

Authors:  Oscar R Herrera; Michael L Christensen; Richard A Helms
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jul-Aug

9.  An inflammation loop orchestrated by S100A9 and calprotectin is critical for development of arthritis.

Authors:  Annabelle Cesaro; Nadia Anceriz; Audrey Plante; Nathalie Pagé; Mélanie R Tardif; Philippe A Tessier
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

10.  Neutrophil calprotectin identifies severe pulmonary disease in COVID-19.

Authors:  Hui Shi; Yu Zuo; Srilakshmi Yalavarthi; Kelsey Gockman; Melanie Zuo; Jacqueline A Madison; Christopher Blair; Wrenn Woodward; Sean P Lezak; Njira L Lugogo; Robert J Woods; Christian Lood; Jason S Knight; Yogendra Kanthi
Journal:  J Leukoc Biol       Date:  2020-09-01       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.